

Press Release



Organizational Changes, Changes in Corporate Officers' Responsibilities, and Personnel Changes

TOKYO, September 4, 2026 - ASKA Pharmaceutical Holdings Co., Ltd. (TSE: 4886, Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi) announced the following organizational changes, changes in corporate officers' responsibilities, and personnel changes, effective October 1, 2026.

1. Organizational Changes

To achieve “ASKA VISION 2035,” announced on May 20, 2026, and the “Mid-Term Management Plan 2028,” the initial three-year action plan toward its realization, the Company will transfer and reorganize its corporate strategy, business development, and administrative functions with the aim of further enhancing group management.

These changes will clarify the allocation of authority and responsibility, enable agile decision-making, and strengthen the management foundation for sustainable growth.

- (1) The Corporate Planning Department under the Group Business Management Division will be abolished, and its corporate planning functions will be transferred. To strengthen the functions for formulating and executing company-wide strategies, the Group Corporate Strategy Division will be newly established, with the Group Corporate Strategy Office and the Group Management Department under it.
- (2) The Audit Department will be reorganized as the Group Audit Office, and the Legal Affairs & Regulatory Compliance Department will be reorganized as the Group Regulatory Compliance Office. In addition, the legal affairs function currently performed by the latter department will be separated, and the Group Legal Affairs Department will be newly established under the Group Business Management Division.
- (3) To support business development across the Group, the Group Business Development Division will be newly established at ASKA Pharmaceutical Holdings Co., Ltd., with the Group Business Development Department under it.

2. Changes in Corporate Officers' Responsibilities

Kiyohiko Tamura	[New Responsibilities]
	Executive Corporate Officer
	Group Business Management Division Director
	In Charge of DX Promotion
	Concurrently, Group Legal Affairs Department Director,
	Group Business Management Division
	[Current Responsibilities]
	Executive Corporate Officer
	Group Business Management Division Director
	In Charge of DX Promotion

Tomohito Nagao	[New Responsibilities] Corporate Officer In Charge of Group Audit and Group Compliance Concurrently, Group Compliance Office Director [Current Responsibilities] Corporate Officer In Charge of Audit and Legal Affairs & Regulatory Compliance
----------------	---

3. Personnel Changes

Junko Komatsu	[New Responsibilities] Group Business Development Division Director [Current Responsibilities] -
Naoaki Shibata	[New Responsibilities] Group Business Development Department Director, Group Business Development Division [Current Responsibilities] -
Hideaki Kobayashi	[New Responsibilities] Group Corporate Strategy Division Director [Current Responsibilities] Assistant Division Director, Group Business Management Division
Kazuko Tamada	[New Responsibilities] Group Corporate Strategy Office Director, Group Corporate Strategy Division [Current Responsibilities] -
Manabu Ichikawa	[New Responsibilities] Group Management Department Director, Group Corporate Strategy Division [Current Responsibilities] Corporate Planning Department Director, Group Business Management Division
Shinya Yamada	[New Responsibilities] Group General Affairs Department Director, Group Business Management Division [Current Responsibilities] Section Manager, Corporate Planning Department, Group Business Management Division

Reference (As of October 1, 2026)

1. Board Members (excluding Board Members who are Audit & Supervisory Committee Members)

Takashi Yamaguchi	Member of the Board of Directors, Representative Director, Chairman of the Board (Member of the Board of Directors, Representative Director, Chairman of the Board of ASKA Pharmaceutical Co., Ltd.)
Sohta Yamaguchi	President, Member of the Board of Directors, Representative Director (President, Member of the Board of Directors, Representative Director of ASKA Pharmaceutical Co., Ltd.)
Atsushi Maruo	Senior Managing Member of the Board of Directors, Representative Director, In Charge of Sustainability (Member of the Board of Directors, Vice Chairman of the Board of ASKA Pharmaceutical Co., Ltd.)
Maiko Mori	Member of the Board of Directors, Executive Corporate Officer (Member of the Board of Directors, Executive Corporate Officer, Quality & Safety Assurance Division Director of ASKA Pharmaceutical Co., Ltd.)
Fumiyoshi Yamaguchi	Member of the Board of Directors, Executive Corporate Officer (President, Member of the Board of Directors, Representative Director of ASKA Animal Health Co., Ltd.)
Minoru Awabayashi	Member of the Board of Directors, Outside Director
Yasuji Enokido	Member of the Board of Directors, Outside Director
Kanae Karita	Member of the Board of Directors, Outside Director
Kiyoko Kato	Member of the Board of Directors, Outside Director
James C. Feliciano	Member of the Board of Directors, Outside Director

2. Board Members who are Audit & Supervisory Committee Members

Kunihiro Gunji	Member of the Board of Directors, Audit and Supervisory Committee Member (Audit & Supervisory Board Member of ASKA Pharmaceutical Co., Ltd., Audit & Supervisory Board Member of ASKA Pharma Medical Co., Ltd.)
Takao Kimura	Member of the Board of Directors, Outside Director, Audit and Supervisory Committee Member
Koki Yamashita	Member of the Board of Directors, Outside Director, Audit and Supervisory Committee Member

3. Corporate Officers

Kiyohiko Tamura	Executive Corporate Officer, Group Business Management Division Director In Charge of DX Promotion Group Legal Affairs Department Director (Executive Corporate Officer, Administrative Division Director of ASKA Pharmaceutical Co., Ltd.)
Tomohito Nagao	Corporate Officer, In Charge of Group Audit and Group Compliance, Group Compliance Office Director (Corporate Officer, Promotion Compliance Unit Director of ASKA Pharmaceutical Co., Ltd.)
Hidenori Hori	Corporate Officer (President, Member of the Board of Directors, Representative Director of ASKA Pharma Medical Co., Ltd.)

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp